| |
Thursday, December 7, 2023 | 2pm ET / 11am PT In this webinar, explore proven strategies, technology insights, and practical approaches to drive innovation, ensure data reproducibility, and unlock the potential of the Lab of the Future. Register now. 
|
|
Today’s Big NewsNov 28, 2023 |
|
Decemeber 5, 2023 | The Edison Ballroom, NYC A celebration of the 50 key players, changemakers and innovators across biotech, pharma and healthcare. The Fierce 50 is a groundbreaking project to identify, elevate and celebrate the individuals and companies driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare. Register Now! 
|
|
| By Angus Liu In a blow to CAR-T therapies, the FDA is investigating a “serious risk” of patients developing new cancers after treatment with these highly efficacious oncology drugs. |
|
|
|
By Annalee Armstrong Acelyrin sent a chill rippling through the IPO market in September when its phase 3 clinical trial unexpectedly failed. But now the company says some errors by the contract research organization running the study may have been to blame. |
By Andrea Park As it awaits regulatory clearance for its Tumor Treating Fields technology in non-small cell lung cancer—and in the wake of the technology’s recent trial failure in ovarian disease—Novocure is narrowing its pipeline and its workforce to conserve funds. |
By Angus Liu Novartis is getting more optimistic about its midterm sales potential, thanks to bullish estimates for some blockbuster drugs, including Entresto and Kisqali. |
By Nick Paul Taylor Merck & Co. has revealed data from a phase 3 trial designed to knock Pfizer’s pneumococcal vaccine off its perch. The vaccine candidate matched Prevnar 20 for shared serotypes and performed better for 10 of its 11 unique serotypes, positioning Merck to file for approvals around the world. |
By Nick Paul Taylor Patient groups are taking matters into their own hands. Frustrated by pharma’s reluctance to engage on environmental, social and governance (ESG) topics, patient representatives are pushing for a bigger role in shaping policies—and are considering the subject when deciding whether to work with a company. |
By Conor Hale Thermo Fisher Scientific has had a longstanding agreement with Flagship Pioneering to help supply the incubator’s roster of young biotechs with life sciences hardware and research services. Now, Thermo Fisher is getting in on the startup game itself. |
By Annalee Armstrong Aldeyra Therapeutics had prepared for the worst and now it's here. The FDA has rejected the dry eye drug reproxalap. |
By Zoey Becker The agreement comes after a patent board ruled that two Teva patents were invalid. Meanwhile, the companies continue to battle it out in a larger case relating to nine of Teva's Ajovy patents. |
By Andrea Park The tubing used to subcutaneously deliver insulin from a Tandem Diabetes Care pump is among the latest devices to land in the FDA’s hot seat. |
By Annalee Armstrong Bristol Myers Squibb seems to have found a friend in Avidity Biosciences, as the two add a second link to a heart-focused research partnership for $100 million upfront. |
By Conor Hale The Penditure is a small, curved clip made to seal off a small pocket in the heart's left atrium, where potentially dangerous blood clots are more likely to form if a person has an irregular heartbeat. |
By Fraiser Kansteiner As the pandemic eased earlier this year, officials in Poland became vocal critics of the financial obligations laid down by Pfizer’s large vaccine supply pact with the European Union. Now, months after the country asked for a reprieve from the costs imposed by the 2021 agreement, Pfizer is targeting Poland in court. |
Fierce podcasts Don’t miss an episode |
| This episode of "The Top Line" is dedicated to Alzheimer’s disease, spotlighting the latest treatments and what lies ahead. Fierce Pharma's Fraiser Kansteiner discusses Leqembi's full approval with Eisai's Alexander Scott. Annalee Armstrong from Fierce Biotech interviews Alzheimer's expert Howard Fillit, M.D., exploring groundbreaking research. Fierce Pharma’s Eric Sagonowsky speaks with Reisa Sperling, M.D., about Leqembi's potential in preventing Alzheimer’s progression before symptoms emerge. |
|
|---|
|
|
|
Thursday, December 7, 2023 | 2pm ET / 11am PT Unlock the secrets to affordable autologous cell therapy manufacturing! Join our webinar to learn about cutting-edge solutions. Discover cost-effective closed-system designs for commercial scale production, bridging the gap between innovation and accessibility. Don't miss out on valuable insights into minimizing expenses in labor, equipment, materials, and facility footprint. Register now. 
|
|
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Download our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
Whitepaper This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| Edison Ballroom, New York City |
|
|
| |
|
